Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Cancer Lett. 2018 Jul 6;433:259–272. doi: 10.1016/j.canlet.2018.07.004

Fig. 2. SIS3 reverses multidrug resistance mediated by ABCB1and ABCG2 in cancer cell lines.

Fig. 2.

Drug-sensitive KB-3–1 cells (A and B, left panel) and MDR variant KB-V-1 cancer cells (A and B, right panel), HEK293 cells (C, left panel) and MDR19-HEK293 cells (C, right panel), drug-sensitive S1 colon cancer cells (D and E, left panel) and MDR variant S1-M1–80 cancer cells (D and E, right panel), as well as HEK293 cells (F, left panel) and R482-HEK293 cells (F, right panel), were treated with increasing concentrations of paclitaxel (A), colchicine (B and C), mitoxantrone (D), SN-38 (E and F) in the presence of DMSO (empty circles), or SIS3 at 0.1 μM (filled circles), 0.2 μM (empty squares), 0.5 μM (filled squares) or 0.7 μM (empty triangles). Points, mean values from at least three independent experiments; bars; SEM.